Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN : NSDQ)
 
 • Company Description   
Freeline Therapeutics Holdings plc is a clinical-stage biotechnology company. It is focused on AAV-based gene therapy targeting the liver. The company operates principally in Germany and the U.S. Freeline Therapeutics Holdings plc is headquartered in the U.K.

Number of Employees: 235

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.74 Daily Weekly Monthly
20 Day Moving Average: 111,641 shares
Shares Outstanding: 35.92 (millions)
Market Capitalization: $26.44 (millions)
Beta: 0.27
52 Week High: $14.02
52 Week Low: $0.65
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -21.70% -14.21%
12 Week -34.87% -29.33%
Year To Date -62.83% -55.80%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
STEVENAGE BIOSCIENCE CATALYST TEVENAGE
-
HERTFORDSHIRE,X0 SG1 2FX
GBR
ph: 44-0-14-3890-6870
fax: -
ir@freeline.life http://www.freeline.life
 
 • General Corporate Information   
Officers
Michael J. Parini - Chief Executive Officer and Executive Director
Christopher Hollowood - Chairman
Benjamin Warriner - Vice President; Finance
Stephen P. Diamond - Senior Vice President; General Counsel & Company S
Markus Horer - Founder; Chief Technology Officer and Managing Dir

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 35655L107
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 35.92
Most Recent Split Date: (:1)
Beta: 0.27
Market Capitalization: $26.44 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.93 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.22
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 35.71%
vs. Previous Quarter: 35.05%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -91.56
12/31/21 - -82.79
09/30/21 - -
ROA
03/31/22 - -74.56
12/31/21 - -75.06
09/30/21 - -
Current Ratio
03/31/22 - 4.82
12/31/21 - 6.20
09/30/21 - 8.82
Quick Ratio
03/31/22 - 4.82
12/31/21 - 6.20
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 3.30
12/31/21 - 3.36
09/30/21 - 4.27
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - -
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - -
 

Powered by Zacks Investment Research ©